Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

GLMD Stock - Galmed Pharmaceuticals Ltd Stock Trading


home / stock / glmd

GLMD GLMD Quote GLMD Short GLMD News GLMD Articles GLMD Message Board

MWN AI Summary *

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a biotechnology company focused on developing innovative therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2010 and headquartered in Tel Aviv, Israel, Galmed aims to address the growing epidemic of liver diseases that affect millions worldwide.

The company’s lead product candidate, Aramchol, is a unique compound derived from a fatty acid that modulates lipid metabolism and targets liver fibrosis. Aramchol is currently undergoing clinical trials aimed at demonstrating safety and efficacy in patients with NASH, a condition characterized by fat buildup in the liver, which can progress to severe liver damage and cirrhosis. The promising potential of Aramchol has garnered attention in the biotech community.

In recent developments, Galmed has made significant progress in its clinical trials. Phase 2 studies have provided encouraging data regarding the drug's safety profile and its potential to reduce liver fat content, with ongoing Phase 3 trials anticipated to further confirm its efficacy in a larger cohort. Additionally, Galmed is exploring the potential of Aramchol in combination therapies, which could offer a more comprehensive approach to treating liver diseases.

Financially, Galmed has accessed various funding avenues, including public offerings and collaborations, to support its research and development endeavors. However, like many biotech firms, it faces challenges such as regulatory hurdles and the need for robust clinical trial results to secure partnerships or product approval.

As of now, Galmed Pharmaceuticals represents a potential player in the pharmaceutical arena aiming to tackle complex liver diseases through innovative research. Investors and analysts are keeping a close watch on the outcomes of its ongoing clinical trials, which are crucial for the company’s future trajectory in the competitive biotech landscape.

MWN AI Analysis *

As of October 2023, Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is focused on the development of innovative therapies for liver diseases, particularly nonalcoholic steatohepatitis (NASH) and other metabolic disorders. Given the rising prevalence of these conditions and the lack of effective treatments currently available, the company is positioned in a growing market with significant unmet medical needs.

Recent developments in GLMD's pipeline suggest potential catalysts for investors. The Phase 2b clinical trial of Aramchol, Galmed's lead compound, is crucial as it aims to demonstrate efficacy in reducing liver fat and fibrosis in patients with NASH. Positive results could not only boost confidence in the drug's potential marketability but could also attract partnerships or acquisition interest from larger pharmaceutical companies.

However, investors should remain cautious. The biotechnology sector is highly volatile, and clinical trials carry inherent risks. Delays or failures in the trial stages can lead to significant drops in stock value. It is essential for investors to keep abreast of upcoming trial results and regulatory decisions, as these will likely serve as key drivers of short-term stock performance.

Furthermore, the broader economic environment may also impact GLMD. Factors such as changes in healthcare policy, funding for biotech innovation, and macroeconomic conditions can influence market sentiment and investment flows in small-cap biotech companies.

In conclusion, Galmed Pharmaceuticals presents an intriguing investment opportunity with substantial long-term growth potential if it successfully advances its pipeline. Investors should conduct thorough due diligence, consider risk tolerance, and stay informed on clinical developments. A balanced approach, combining event-driven strategies with a broader view of the biotech landscape, can help navigate the complexities of investing in GLMD.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Quote | Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)

Last:$2.09
Change Percent: 0.55%
Open:$1.82
Close:$2.09
High:$2.09
Low:$1.82
Volume:543,428
Last Trade Date Time:07/08/2025 03:40:35 pm

News | Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)

  • GLMD - Historical Price Movements Surrounding Earnings

    2025-05-27 18:47:42 ET Galmed Pharmaceuticals Ltd. (GLMD) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.31%. The average open to low on the day of earnings was -6.29%. The average op...

    • May 27, 2025 06:47:42 pm

    • |
    • KlickAnalytics
    • |
      • GLMD Stock
      • GLMD Quote
      • GLMD Short
      • GLMD News
      • GLMD Articles
      • GLMD Message Board
  • Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

    Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH PR Newswire Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, un...

    • May 27, 2025 08:00:00 am

    • |
    • PR Newswire
    • |
      • GLMD Stock
      • GLMD Quote
      • GLMD Short
      • GLMD News
      • GLMD Articles
      • GLMD Message Board

Message Board Posts | Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)

Subject By Source When
https://ih.advfn.com/stock-market/NASDAQ/galmed-pharmaceuticals-$GLMD/historical HoldEm777 investorshub 05/07/2023 6:28:07 PM
https://stockcharts.com/h-sc/ui?s=glmd&p=D&yr=0&mn=6&dy=0&id=p38090673899 htt surf1944 investorshub 05/07/2023 2:51:20 PM
$GLMD MomentumIts gaining last up DewDiligence investorshub 05/07/2023 1:31:18 AM
Price now DewDiligence investorshub 05/05/2023 11:29:33 AM
$GLMD Galmed Pharmaceuticals forms a Strategic Partnership with OnKai Golden Cross investorshub 05/04/2023 8:45:26 PM

MWN AI FAQ **

What recent developments or clinical trial results have impacted Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) stock performance in the last quarter?

In the last quarter, Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) experienced stock volatility primarily due to the announcement of interim data from its clinical trials for Aramchol, which showed promise in treating non-alcoholic fatty liver disease, attracting investor interest.

How does Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) plan to address regulatory challenges for its drug candidates moving forward?

Galmed Pharmaceuticals Ltd. plans to address regulatory challenges for its drug candidates by engaging with regulatory authorities early in the development process, ensuring robust clinical data, and adapting strategies based on feedback to enhance the likelihood of approval.

What partnerships or collaborations has Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) established to enhance its R&D efforts?

Galmed Pharmaceuticals Ltd. has established collaborations with the University of California, San Diego and various research institutions to enhance its R&D efforts, particularly focusing on advancing its lead drug candidate, Aramchol, for treating liver diseases.

How does Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) differentiate its pipeline from competitors in the biotech industry?

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) differentiates its pipeline from competitors by focusing on innovative liver disease treatments, particularly its lead compound, Aramchol, which targets metabolic disorders and steatohepatitis through a unique mechanism of action.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get GLMD Alerts

News, Short Squeeze, Breakout and More Instantly...

Galmed Pharmaceuticals Ltd. Company Name:

GLMD Stock Symbol:

NASDAQ Market:

0.55% G/L:

$2.09 Last:

543,428 Volume:

$1.82 Open:

$2.09 Close:

Galmed Pharmaceuticals Ltd. Website:

Galmed Pharmaceuticals Ltd. Logo

Ad

Investor Relations
RECENT GLMD NEWS
  • GLMD - GLMD - Historical Price Movements Surrounding Earnings

    2025-05-27 18:47:42 ET Galmed Pharmaceuticals Ltd. (GLMD) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.31%. The average open to low on the day of earnings was -6.29%. The average op...

  • GLMD - Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

    Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH PR Newswire Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, un...

  • GLMD - Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get GLMD Alerts

Get GLMD Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1